Tina Katcheves gained professional experience from both Teva Pharmaceuticals and Bristol Myers Squibb on August 27, 2025, involving Acadia Pharmaceuticals.
2 reports, 2 independent
Updated Aug 27
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Tina Katcheves gained professional experience from both Teva Pharmaceuticals and Bristol Myers Squibb on August 27, 2025, involving Acadia Pharmaceuticals.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Bristol-Myers Squibb
American pharmaceutical company
-
Acadia Pharmaceuticals
Pharmaceutical company, which developed Nuplazid, based in San Diego, California.
Nothing else this week.
-
Teva Pharmaceutical Industries Ltd.
Israeli pharmaceutical company
Coverage
Newest first; wire copies grouped- Simply Wall St.How Investors May Respond To ACADIA Pharmaceuticals (ACAD) Hiring an Industry Veteran for Growth Strategy On August 25, 2025, Acadia Pharmaceuticals announced the appointment of Konstantina (“Tina”)
- Business WireAcadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer SAN DIEGO, August 25, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: A